BioTuesdays
Intra Cellular Therapies

BTIG starts Intra-Cellular Therapies at buy

BTIG launched coverage of Intra-Cellular Therapies (NASDAQ:ITCI) with a “buy” rating and $44 price target, saying there is considerable promise for the company’s antipsychotic, ITI-007, in multiple indications. The...

Catabasis Pharma

HCW starts Catabasis Pharma at buy

H.C. Wainwright initiated coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $14 price target. The stock closed at $3.59 on Dec. 21. “The SMART Linker technology is key to our investment...

CoLucid Pharmaceuticals

BTIG starts CoLucid Pharma at buy

BTIG initiated coverage of CoLucid Pharmaceuticals (NASDAQ:CLCD) with a “buy” rating and $58 price target, calling the company’s Lasmiditan drug candidate a game changer in acute migraine. The stock closed at $36.16 on...

Cellectar Biosciences

Ladenburg starts Cellectar Biosciences at buy

Ladenburg Thalmann launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $2.70 price target. The stock closed at $1.24 on Dec. 20. Cellectar is focused on development of phospholipid-ether...

IRIDEX

Roth starts IRIDEX at buy

Roth Capital Partners initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $20 price target. The stock closed at $13.22 on Dec. 20. Iridex is an ophthalmic medical device company focused on development and...

Cidara Therapeutics Logo

HCW starts Cidara Therapeutics at buy

H.C. Wainwright launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $25 price target. The stock closed at $10.80 on Dec. 16. Cidara’s lead drug, CD101 IV, is a novel molecule in the...

Arbutus Biopharma Logo

Arbutus, Spring Bank in HBV collaboration

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV). The accord involves the co-administration of Spring...

Histogenics

HCW starts Histogenics at buy

H.C. Wainwright initiated coverage of Histogenics (NASDAQ:HSGX) with a “buy” rating and price target of $3.50, saying the company has an innovative product with significant market potential. The stock closed at $1.58 on...

Adamis Pharma

Adamis resubmits NDA to FDA for epinephrine pen

Adamis Pharmaceuticals (NASDAQ:ADMP) has resubmitted its NDA to the FDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. The resubmission is intended to address...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.